contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-publishes-its-h12025-report-invitation-to-a-webinar

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Note, latest timing info!  Herantis expects to report the Phase 1b biomarker data by mid-January 2026, in advance of the JP Morgan Healthcare Conference week in San Francisco, where the Company’s management will be available for meetings.  Herantis plans to initiate a Phase 2 clinical trial in 2026 to evaluate the efficacy, safety, and tolerability of HER-096 in people with Parkinson’s disease.

This link contains key information about an approved, commonly used medication for the “treatment” of Parkinson’s disease. Much seems to be based on guesswork regarding the mechanism of action and contraindications. Hopefully, Herantis Pharma’s HER-096 gets on the fast track.            organon.com              sinemet_pi.pdf

Yeah, exactly. In principle, it goes like this: In the analysis, a required rate of return (WACC) is given to the shares. If the difference between the current share price and the target price is > the required rate of return, then the recommendation is positive. If the difference is < WACC, then the recommendation is negative. However, in drug development companies, WACC does not describe the company’s risk very well because a significant part of the risk is priced into risk-adjusted forecasts (i.e., the probability of research success) instead of WACC. Therefore, in these companies, the required rate of return is practically greater than WACC.

Herantis Pharma | Edison  webinar  https://youtu.be/OZbyxHiHc0w?si=tk6Czn33xwUvMKc6

Herantis Pharma Plc | Press release | 26 November 2025, at 12:00 EET Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096 Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previous pre-clinical and clinical data. These results provide further confidence in the compound’s suitability for long-term administration and represent another important milestone on the path towards a Phase 2 clinical efficacy trial. “The successful completion of this long-term toxicology study marks another important step forward for our HER-096 program”, said Henri Huttunen, CSO of Herantis Pharma. “Together with the positive results from our Phase 1b trial, we now have a comprehensive safety and pharmacokinetic dataset that provides a strong foundation for advancing HER-096 into Phase 2 clinical development. We are excited by the growing body of evidence for HER-096 as a potentially game-changing therapy that could become the first disease-modifying and neurorestorative treatment for Parkinson’s disease.” The completion of the preclinical toxicology program also marks the final milestone of the EIC Accelerator Grant project, which began in 2023. The grant of EUR 2.5 million also enabled Herantis to advance its biomarker development program, the results of which have already been applied in exploratory biomarker analyses within the Phase 1b clinical trial.

Approximately 30-60 days were supposed to be spent on marker counting. October 25th was likely the day the phase ended. Perhaps they will hold onto the marker data a bit longer, and then something will happen in JP.

Can’t you read “between the lines” from that, that the biomarker results were good? It had surprisingly little effect on the stock price, as after the morning jump, we have already slid back to the starting position.

Herantis Pharma

Herantis Pharma Plc | Press Release | 7 August 2025 at 11:30 EEST.Herantis Pharma publishes its H1/2025 Report – invitation to a webinarEspoo, Finland, 7 August 2025: Herantis Pharma, a clinical...

Herantis Pharma Plc | Press Release | 7 August 2025 at 11:30 EEST.Herantis Pharma publishes its H1/2025 Report – invitation to a webinarEspoo, Finland, 7 August 2025: Herantis Pharma, a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, will publish its H1/2025 Report on Thursday, 21st August 2025 at 8:00 EEST (7:00 CEST). The report will be available on the company website after publication.Webcast on Thursday, 21st of August at 10:00 EEST (9:00 CEST)Herantis CEO Antti Vuolanto and CFO Tone Kvåle will present the results of H1 and the status of the operations, followed by Q&amp;A session. Questions can be submitted throughout the webcast event. Participants are invited to ask questions in English. The event and presentation will be held in English.Shareholders, investors, analysts and media are invited to pre-register and join the online event using the following link: <a href="https://herantis.videosync.fi/q2-2025">https://herantis.videosync.fi/q2-2025</a>The recording of the webcast will be available at the company’s website at <a href="https://herantis.com/news-events/public-materials/">https://herantis.com/news-events/public-materials/</a>For more information, please contact:Herantis Pharma Plc Tone Kvåle, CFO Tel: +47 915 19576 Email: ir@herantis.comICR Healthcare Mary-Jane Elliott, Sarah Elton-Farr, Stephanie Cuthbert Tel: +44 20 3709 5700 Email: <a href="mailto:herantispharma@icrhealthcare.com">herantispharma@icrhealthcare.com</a>Certified Advisor: UB Corporate Finance Ltd Tel: +358 9 25 380 225 Email: <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma Plc Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. HER-096 is currently being evaluated in a Phase 1b clinical trial to assess the safety and tolerability of repeated subcutaneous dosing in patients with Parkinson’s disease. The study builds on positive Phase 1a results, where HER-096 demonstrated a favourable safety and tolerability profile, and effective brain penetration in healthy volunteers.Herantis is listed on the Nasdaq First North Growth Market Finland.Company website: <a href="http://www.herantis.com">www.herantis.com</a>